Prescription medication · Nucleoside Analog (Antiviral)
molnupiravir
Also sold as Lagevrio. Lagevrio treats mild-to-moderate COVID-19 in adults.
Data updated 2026-05-15
- 5,119
- FDA reportsLightly reported
- Rx
- Availability
molnupiravir (Lagevrio) is a prescription Nucleoside Analog (Antiviral). Lagevrio treats mild-to-moderate COVID-19 in adults.
Lagevrio contains molnupiravir, an antiviral medicine. It is used to treat COVID-19 in adults.
Verify with FDA → · CMS NADAC pricing →
What it does
Lagevrio treats mild-to-moderate COVID-19 in adults.
Common side effects
Diarrhea, Nausea, Dizziness
Key warnings
Lagevrio is only for adults with mild-to-moderate COVID-19 who are at high risk of severe illness and when other treatments aren't suitable.
The sections below are summarized in plain English from molnupiravir's FDA-approved prescribing information. They describe what the official label says, and are not personal medical advice.
How It Works
Lagevrio stops the COVID-19 virus from multiplying in your body. It does this by interfering with how the virus makes copies of itself. This helps your body fight off the infection.
Side Effects (from patient reports)
Based on 5,119 FDA adverse event reports.
Most-reported reactions
Adverse reactions in FAERS for molnupiravir, by number of reports
- Covid-19
Covid-19
476 reports
- Diarrhoea
Diarrhoea
268 reports
- Product Use Complaint
Product Use Complaint
212 reports
- Rash
Rash
210 reports
- Accidental Underdose
Accidental Underdose
207 reports
- Nausea
Nausea
191 reports
- Underdose 184
Underdose
184 reports
- Accidental Overdose 152
Accidental Overdose
152 reports
- Vomiting 144
Vomiting
144 reports
- Dizziness 138
Dizziness
138 reports
What this shows Bars show how often each reaction was reported, not how likely it is to happen, a report records a temporal association, never proof that the drug caused it.
Reports over time
Adverse-event reports filed for molnupiravir each year to the FDA Adverse Event Reporting System (FAERS).
Year-to-year volume tracks usage, prescribing, and scrutiny, not a change in per-patient risk. Source: FDA FAERS.
Where molnupiravir sits
molnupiravir has more FDA adverse-event reports than 25% of the drugs FAERS tracks. A high position reflects how widely a drug is used and watched, not how dangerous it is.
Percentile across all drugs PlainMeds tracks by FAERS report volume. The dot is molnupiravir; the line is the median (50th percentile).
FDA Adverse Event Report Analysis
Detailed analysis of 5,119 reports from the FDA Adverse Event Reporting System (FAERS). Reports span 2018–2025.
Total Reports
5,119
Reports Mentioning Death
472
9.2% of reports — not proof of cause
Hospitalization Reports
933
Top Indication
Covid-19 Treatment
Gender Distribution
Age Distribution
Most Reported Adverse Reactions (FAERS)
| # | Reaction | Reports |
|---|---|---|
| 3 | COVID-19 | 476 |
| 6 | DIARRHOEA | 268 |
| 7 | PRODUCT USE COMPLAINT | 212 |
| 8 | RASH | 210 |
| 9 | ACCIDENTAL UNDERDOSE | 207 |
| 10 | NAUSEA | 191 |
| 11 | UNDERDOSE | 184 |
| 13 | ACCIDENTAL OVERDOSE | 152 |
| 14 | VOMITING | 144 |
| 15 | DIZZINESS | 138 |
| 16 | INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION | 137 |
| 17 | OVERDOSE | 117 |
| 18 | PRODUCT PRESCRIBING ISSUE | 113 |
| 19 | COVID-19 PNEUMONIA | 105 |
| 20 | DEATH | 103 |
Reactions in Death Reports
Reactions in Hospitalization Reports
Source: FDA FAERS (Adverse Event Reporting System) Reports are voluntary and do not establish causation
Serious Warnings
Lagevrio is only for adults with mild-to-moderate COVID-19 who are at high risk of severe illness and when other treatments aren't suitable. Tell your doctor if you are pregnant or plan to become pregnant. Lagevrio may harm your unborn baby. Females who can get pregnant should use birth control during treatment and for 4 days after the last dose. Males who can get someone pregnant should use birth control during treatment and for 3 months after the last dose.
Common Questions
What should I do if I experience an allergic reaction?
Can I take Lagevrio if I have kidney problems?
Can I take Lagevrio if I have liver problems?
Can older people take Lagevrio?
Are there any known drug interactions with Lagevrio?
Can children or teenagers take Lagevrio?
What if I can't swallow the capsules?
How long should I take Lagevrio?
What if I start feeling better before finishing the 5-day course?
Is Lagevrio a substitute for vaccination?
What are the common side effects of molnupiravir?
What drug class is molnupiravir?
What pregnancy or breastfeeding source fields are listed for molnupiravir?
Related Medications in Nucleoside Analog (Antiviral)
Other drugs grouped near molnupiravir - same-class peers and common alternatives.
acyclovir
Zovirax
Acyclovir is an antiviral medicine.
Compare with molnupiravir →
albendazole
Albenza
Albendazole is a medicine that fights parasites.
Compare with molnupiravir →
amphotericin B
Ambisome, Fungizone
Amphotericin B liposome is an antifungal medicine.
Compare with molnupiravir →
anidulafungin
Eraxis
Eraxis is an antifungal medicine.
Compare with molnupiravir →
atovaquone/proguanil
Malarone
Malarone is a drug used to prevent and treat malaria.
Compare with molnupiravir →
Compare beyond drug class
Nationwide peers by FAERS volume & death-report share
Two PlainMeds-derived comparison paths for molnupiravir: nearest FDA FAERS report volume and nearest death-report share among drugs with at least 1,000 logged reports, excluding same-class neighbors listed above. Counts reflect reporting volume, not proven individual harm.
Similar FAERS report volume
Nearest drugs by total FAERS reports. This record: 5,119.
Similar death-report share
Nearest drugs by FAERS death-report share. This record: 9.22%.
- aspirin Δ 0.00 pts · 518,554 reports · Antiplatelet / NSAID 9.22%death share
- valsartan Δ 0.00 pts · 102,306 reports · Angiotensin II Receptor Blocker (ARB) 9.22%death share
- ketoprofen Δ 0.01 pts · 12,302 reports · Nonsteroidal Anti-Inflammatory Drug (NSAID) 9.23%death share
- bismuth subsalicylate Δ 0.05 pts · 5,567 reports · Antidiarrheal / Antacid 9.27%death share
Medication Guides
Understanding Drug Interactions
How CYP450 enzymes, inhibitors, and inducers affect your medications
Generic vs Brand Name Drugs
FDA requirements, cost savings, and when the difference matters
Narrow Therapeutic Index Drugs
FDA bioequivalence and label-record context for narrow therapeutic index medicines
Common Drug Interactions
Dangerous medication combinations and how to protect yourself
Save on molnupiravir
Compare prices and find discounts at pharmacies near you. Free coupons can save up to 80% on prescriptions.
Disclosure: This link may earn us a commission at no extra cost to you. See our terms.
What the FDA Data Shows for molnupiravir
The FDA label for molnupiravir (sold under brand names such as Lagevrio) classifies it as a prescription-only medication in the Nucleoside Analog (Antiviral) class. Lagevrio treats mild-to-moderate COVID-19 in adults. Official labeling lists 3 commonly reported side effects, including Diarrhea, Nausea, Dizziness.
Post-market surveillance from the FDA Adverse Event Reporting System (FAERS) captures real-world experience. For this drug, FAERS contains 5,119 voluntary reports. Interaction data is drawn directly from FDA-approved prescribing information. Acquisition-cost data is surveyed weekly by CMS and updated as manufacturers report changes.
Report counts do not establish causation, a FAERS entry documents a temporal association, not proof that the drug produced the outcome. Widely prescribed medications naturally accumulate more reports than niche therapies, so raw totals must be interpreted alongside total exposure. Shortage status, recall history, and patent information are separate source-record fields. This page is a public FDA/CMS registry and does not provide medical, treatment, substitution, or medication-change directions.
Data Sources
Drug labeling: FDA Drug Labels (SPL/DailyMed). Adverse events: FDA Adverse Event Reporting System (FAERS).
FAERS reports are voluntary and do not establish causation. Drug interactions are derived from FDA labeling and clinical references. This registry does not provide medication decisions.
Last updated: July 11, 2025
PlainMeds is rendered directly from FDA openFDA/FAERS extracts, DailyMed labels, and CMS drug-pricing files, no number is typed in by an editor. FAERS counts, recalls, shortages, and price figures on this page are queried live from those federal extracts. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-05-15. Primary sources: openFDA / FAERS, DailyMed and CMS Part B ASP.
Read our methodology - how this data is sourced, computed, and verified.
Data currency: FDA FAERS adverse-event reports through 2025, CMS NADAC acquisition-cost pricing effective December 2024, compiled from the source snapshot dated . See our methodology for per-source dates and refresh cadence. Spot a figure that looks wrong? Report a data issue.
All federal data sources used on this page
- FDA Orange Book - approved drug products with therapeutic equivalence. accessdata.fda.gov/cder/ob
- FDA DailyMed - NIH-hosted drug labeling for FDA-approved meds. dailymed.nlm.nih.gov
- FDA Adverse Event Reporting System (FAERS) - post-marketing safety surveillance. fda.gov/drugs/faers
- NLM RxNorm - standardized clinical drug nomenclature. nlm.nih.gov/research/umls/rxnorm
- CMS Medicare Part B Drug Average Sales Price Files - federal drug pricing data. cms.gov/medicare/part-b-drugs/asp
- FDA Drug Shortages Database - current and resolved drug shortage tracking. accessdata.fda.gov/drugshortages